Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419770 · ClinicalTrials.gov registry record · Phase 2
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
A Phase 2 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00419770 is a Phase 2 study that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT00419770, a Phase 2 study, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
Interventions
- DRUG Placebo
- DRUG deferasirox
- DRUG Liposomal amphotericin B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419770
The ClinicalTrials.gov registry entry for NCT00419770 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00419770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00419770 about?
NCT00419770 is a clinical study titled "The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study". The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
What is the current status of trial NCT00419770?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00419770?
The interventions under investigation include: Placebo (DRUG), deferasirox (DRUG), Liposomal amphotericin B (DRUG).
Who is sponsoring clinical trial NCT00419770?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.